Savara(US:SVRA) Prnewswire·2025-10-23 17:36Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [3][4]. Group 1: Allegations Against Savara - The complaint alleges that Savara and its executives made false and misleading statements regarding the MOLBREEVI BLA, including insufficient information about its chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission process and increase the likelihood of the company needing to raise additional capital [3]. - Following the announcement of a refusal to file letter from the FDA, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased securities in Savara between March 7, 2024, and May 23, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of November 7, 2025, to seek the role of lead plaintiff in the class action [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [5]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [5].